The patents cover sales of Biogen products for MS that are covered by a Forward Pharma patent and have dimethyl fumarate as an active pharmaceutical ingredient. The two companies say they intend ...

On today's stock market, Biogen stock popped 4.6% to 201.99. "Some encouraging signs of life for the launch products," he said in a client note. "While the base business continues to compress and ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Per deal terms, the Massachusetts-based biotechnology company also granted Biogen an option to license rights to certain follow-on products that work in similar ways as zorevunersen. The drug is ...

As an independent biotechnology company, Biogen (Cambridge ... was approved in Europe in 1998. The three IFN products were tested based on known immunomodulatory and anti-viral effects of type ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Needham also highlighted that other key Biogen products, such as Skyclarys and Zurzuvae, are expected to ramp up slowly, but may not be sufficient to offset declines in the company's base business ...

Stoke has also granted Biogen an option to license rights outside of the United States, Canada, and Mexico to certain future follow-on ASO products targeting SCN1A, in exchange for separate ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK ... the Committee for Medicinal Products for Human Use (CHMP), an expert panel of the European Medicines Agency, recommended lecanemab for a narrower group ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...